Ben S Wittner
Overview
Explore the profile of Ben S Wittner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
8517
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mishra A, Huang S, Dubash T, Burr R, Edd J, Wittner B, et al.
Nat Commun
. 2025 Jan;
16(1):32.
PMID: 39746954
Circulating Tumor Cells (CTCs) in blood encompass DNA, RNA, and protein biomarkers, but clinical utility is limited by their rarity. To enable tumor epitope-agnostic interrogation of large blood volumes, we...
2.
Mishra A, Huang S, Dubash T, Burr R, Edd J, Wittner B, et al.
bioRxiv
. 2024 Apr;
PMID: 38559183
Circulating Tumor Cells (CTCs), interrogated by sampling blood from patients with cancer, contain multiple analytes, including intact RNA, high molecular weight DNA, proteins, and metabolic markers. However, the clinical utility...
3.
Guo H, Vuille J, Wittner B, Lachtara E, Hou Y, Lin M, et al.
Cell
. 2023 Jun;
186(13):2765-2782.e28.
PMID: 37327786
Cancer is characterized by hypomethylation-associated silencing of large chromatin domains, whose contribution to tumorigenesis is uncertain. Through high-resolution genome-wide single-cell DNA methylation sequencing, we identify 40 core domains that are...
4.
Dubash T, Bardia A, Chirn B, Reeves B, LiCausi J, Burr R, et al.
Breast Cancer Res Treat
. 2023 Jun;
201(1):43-56.
PMID: 37318638
Purpose: Metastatic hormone receptor-positive (HR+) breast cancer initially responds to serial courses of endocrine therapy, but ultimately becomes refractory. Elacestrant, a new generation FDA-approved oral selective estrogen receptor degrader (SERD)...
5.
Fox D, Ebright R, Hong X, Russell H, Guo H, LaSalle T, et al.
NPJ Precis Oncol
. 2023 Mar;
7(1):25.
PMID: 36864091
Immune checkpoint blockade (ICB) has demonstrated efficacy in patients with melanoma, but many exhibit poor responses. Using single cell RNA sequencing of melanoma patient-derived circulating tumor cells (CTCs) and functional...
6.
TGF-β in the microenvironment induces a physiologically occurring immune-suppressive senescent state
Matsuda S, Revandkar A, Dubash T, Ravi A, Wittner B, Lin M, et al.
Cell Rep
. 2023 Feb;
42(3):112129.
PMID: 36821441
TGF-β induces senescence in embryonic tissues. Whether TGF-β in the hypoxic tumor microenvironment (TME) induces senescence in cancer and how the ensuing senescence-associated secretory phenotype (SASP) remodels the cellular TME...
7.
Karabacak N, Zheng Y, Dubash T, Burr R, Micalizzi D, Wittner B, et al.
Cancer Res
. 2022 Jan;
82(6):1084-1097.
PMID: 35045985
Significance: Single-cell mass cytometry analyses provide insights into the differences in kinase activities across tumor compartments and cell states, which contribute to heterogeneous responses to targeted therapies.
8.
Guo H, Golczer G, Wittner B, Langenbucher A, Zachariah M, Dubash T, et al.
Mol Cell
. 2021 Oct;
81(19):4041-4058.e15.
PMID: 34624217
Deregulation of oncogenic signals in cancer triggers replication stress. Immediate early genes (IEGs) are rapidly and transiently expressed following stressful signals, contributing to an integrated response. Here, we find that...
9.
Sundaresan T, Dubash T, Zheng Z, Bardia A, Wittner B, Aceto N, et al.
Breast Cancer Res Treat
. 2021 Jun;
188(1):43-52.
PMID: 34101078
Purpose: Therapeutic efficacy of hormonal therapies to target estrogen receptor (ER)-positive breast cancer is limited by the acquisition of ligand-independent ESR1 mutations, which confer treatment resistance to aromatase inhibitors (AIs)....
10.
Ebright R, Zachariah M, Micalizzi D, Wittner B, Niederhoffer K, Nieman L, et al.
Nat Commun
. 2020 Dec;
11(1):6311.
PMID: 33298946
Blood-borne metastasis to the brain is a major complication of breast cancer, but cellular pathways that enable cancer cells to selectively grow in the brain microenvironment are poorly understood. We...